Physician profile
Taylor Shaker
NPI 1215390083
$984.54
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $11.24 · 2021: $365 · 2022: $228 · 2023: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $214.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $227.96 | 2021-2023 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $104.33 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Arthrosurface Incorporated | $99.86 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.21 | 2021-2023 | Jardiance |
| Lilly USA, LLC | $83.17 | 2019-2022 | |
| Glaxosmithkline, LLC. | $68.93 | 2021-2023 | Shingrix, Bexsero |
| Amgen INC. | $66.06 | 2021-2023 | Repatha, Otezla |
| Idorsia Pharmaceuticals US INC | $47.66 | 2022-2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $42.71 | 2021 | |
| Pfizer INC. | $27.95 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $25.30 | 2019-2020 | |
| Abbott Laboratories | $19.14 | 2023 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $17.44 | 2022 | |
| Currax Pharmaceuticals LLC | $15.92 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.27 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $14.21 | 2022 | |
| Vertical Pharmaceuticals, LLC | $13.58 | 2019 | |
| Merck Sharp & Dohme LLC | $12.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Shaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.